International sales fuel OEC results

Article

Strong international acceptance of its Series 9600 mobile C-armhas helped OEC Medical Systems record sharply higher revenuesand profits for its second quarter (end-June). The Salt Lake Citycompany had second-quarter revenues of $26.1 million, up 34%

Strong international acceptance of its Series 9600 mobile C-armhas helped OEC Medical Systems record sharply higher revenuesand profits for its second quarter (end-June). The Salt Lake Citycompany had second-quarter revenues of $26.1 million, up 34% overthe $19.4 million in product sales in the same period last year.Net income was $2.8 million, compared to $300,000 in the secondquarter of 1994.

OEC was bedeviled by delays in shipping Series 9600 last yearthat were reflected in the company's 1994 results, but those bugshave been worked out, according to chairman, president and CEORuediger Naumann-Etienne. OEC's numbers this year were aided bystrong international demand for the product. International salesfor the first six months of 1995 have already exceeded the totalrecorded last year, he said.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.